{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T02:44:07Z","timestamp":1786675447032,"version":"build-2736575974"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.clcc.2018.02.005","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T02:20:46Z","timestamp":1519179646000},"page":"307-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy and Safety of Regorafenib With 2\/1 Schedule for Patients\u00a0\u2265 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy"],"prefix":"10.1016","volume":"17","author":[{"given":"Roberto","family":"Petrioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2049-8507","authenticated-orcid":false,"given":"Martina","family":"Chirra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Messuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Ida","family":"Fiaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinno","family":"Savelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazio","family":"Martellucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4270-7023","authenticated-orcid":false,"given":"Edoardo","family":"Francini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2018.02.005_bib1","first-page":"11","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clcc.2018.02.005_bib2","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.dld.2016.05.011","article-title":"Colorectal cancer care in elderly patients: unsolved issues","volume":"48","author":"Aparicio","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.clcc.2018.02.005_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jgo.2017.08.001","article-title":"Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: a systematic review","volume":"9","author":"Gouverneur","year":"2018","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.clcc.2018.02.005_bib4","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/ijc.28669","article-title":"Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer","volume":"135","author":"Schmieder","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clcc.2018.02.005_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1586\/14737140.2014.894887","article-title":"Regorafenib in metastatic colorectal cancer","volume":"14","author":"Sartore-Bianchi","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clcc.2018.02.005_bib6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2018.02.005_bib7","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1093\/annonc\/mds236","article-title":"ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making","volume":"23","author":"Schmoll","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.02.005_bib8","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.02.005_bib9","doi-asserted-by":"crossref","first-page":"e115060","DOI":"10.1371\/journal.pone.0115060","article-title":"Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study","volume":"9","author":"Soubeyran","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clcc.2018.02.005_bib10","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.2002.20.2.494","article-title":"Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study","volume":"20","author":"Repetto","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.02.005_bib11","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1634\/theoncologist.5-3-224","article-title":"Management of cancer in the older person: a practical approach","volume":"5","author":"Balducci","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2018.02.005_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.clcc.2018.02.005_bib13","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2018.02.005_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1634\/theoncologist.2017-0275","article-title":"Propensity score analysis of regorafenib versus trifluridine\/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study","volume":"23","author":"Moriwaki","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2018.02.005_bib15","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s11523-017-0529-y","article-title":"Comparative safety of targeted therapies for metastatic colorectal cancer between elderly and younger patients: a study using the International Pharmacovigilance Database","volume":"12","author":"Gouverneur","year":"2017","journal-title":"Target Oncol"},{"key":"10.1016\/j.clcc.2018.02.005_bib16","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s12885-016-2440-9","article-title":"Survival, safety, and prognostic factors for outcome with regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program","volume":"16","author":"Adenis","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clcc.2018.02.005_bib17","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1186\/1756-0500-7-872","article-title":"Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2\/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases","volume":"7","author":"Makino","year":"2014","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.clcc.2018.02.005_bib18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/annonc\/mdv589","article-title":"Sunitinib administered on 2\/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis","volume":"27","author":"Bracarda","year":"2016","journal-title":"Ann Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002817304863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002817304863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:06:31Z","timestamp":1761519991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002817304863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1533002817304863"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2018.02.005","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Regorafenib With 2\/1 Schedule for Patients\u00a0\u2265 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2018.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}